Zymeworks(US:ZYME) Financial Modeling Prep·2025-11-25 00:00Core Insights - Zymeworks Inc. is a biotechnology company focused on developing innovative biotherapeutics and is participating in two major investor conferences in Miami [1] - The company is advancing its portfolio of licensed healthcare assets, particularly zanidatamab, through strategic partnerships to optimize future cash flows [2] - B. Riley upgraded Zymeworks' stock to a "Buy" rating with a price target increase from $30 to $40, reflecting positive market sentiment [3] Company Developments - Zymeworks has formed partnerships with BeOne Medicines Ltd. and Jazz Pharmaceuticals Ireland Limited for the development and commercialization of zanidatamab [2] - The stock has shown resilience with a 52-week high of $26.19 and a low of $9.03, indicating strong investor interest [4] - The company’s market capitalization is approximately $1.88 billion, with current trading at $24.96, reflecting a 3.91% increase [3][4] Market Position - Zymeworks is well-positioned in the biotechnology sector, focusing on multifunctional biotherapeutics for diseases such as cancer and autoimmune disorders [4] - The company’s integrated drug development engine and therapeutic platforms allow for precise engineering of antibody-based therapeutics [4] - Partnerships with global biopharmaceutical companies enhance Zymeworks' capabilities to target novel pathways in areas with significant unmet medical needs [4]